Korea University Guro Hospital

Onconic's Jaqbo Shows 100% Efficacy in Phase 3 Gastric Ulcer Trial, Seeks Indication Expansion

4 months ago

• Onconic Therapeutics has submitted an application to MFDS to expand Jaqbo's indication to include gastric ulcer treatment, following successful Phase 3 trial results showing 100% healing rate at 8 weeks. • The Phase 3 trial, involving 329 patients across 40 Korean medical institutions, demonstrated non-inferiority of Jaqbo compared to lansoprazole in treating gastric ulcers. • If approved in the first half of 2024, Jaqbo will become a dual-indication treatment for both erosive GERD and gastric ulcers, strengthening its potential as a global blockbuster drug.

Individualized Blood Pressure Management in Major Surgery: SPROUT-4 Trial

5 months ago

• The SPROUT-4 trial is a multicenter, randomized controlled trial evaluating individualized blood pressure management versus conventional methods during major noncardiac surgery. • High-risk patients aged ≥65 years or ≥45 years with cardiovascular risk factors will be enrolled to assess the impact on postoperative outcomes. • The primary outcome is a composite of all-cause death, stroke, myocardial infarction, heart failure, revascularization, and acute kidney injury within 7 days. • The trial aims to determine if maintaining blood pressure at 20% below baseline reduces adverse events compared to maintaining a MAP ≥65 mmHg and SBP ≥90 mmHg.

Amlodipine and Candesartan Combination Therapy Shows Superior Efficacy in Treating Hypertension

8 months ago

• A Phase III clinical trial demonstrates that a combination of amlodipine and candesartan is more effective than amlodipine alone in reducing diastolic blood pressure in hypertensive patients. • The study, involving Korean patients with essential hypertension, showed significant reductions in both diastolic and systolic blood pressure with the combination therapy. • The fixed-dose combination of amlodipine and candesartan was well-tolerated, with adverse events comparable to those observed with amlodipine monotherapy. • These findings support the use of amlodipine and candesartan combination therapy as an effective treatment option for patients whose hypertension is not adequately controlled by amlodipine alone.